Treatment of Female Pattern Hair Loss

Primary Treatment Approach

The American College of Dermatology recommends topical minoxidil 5% foam once daily or 2% solution twice daily as first-line therapy for female pattern hair loss, which must be continued indefinitely to maintain hair growth benefits 1, 2
When topical minoxidil monotherapy proves insufficient after 6-12 months, adding oral hormonal therapy becomes appropriate, with spironolactone being the preferred agent 2

The American Academy of Dermatology suggests that spironolactone 100 mg daily can be started, with doses up to 200 mg/day possible, though side effects increase at higher doses 3
Concomitant use of combined oral contraceptives or hormonal IUD minimizes menstrual irregularities and provides necessary pregnancy prevention when using spironolactone, which is pregnancy category C with risk of male fetus feminization 3, 4
Potassium monitoring is unnecessary in young healthy women without renal disease, hypertension, heart disease, or use of ACE inhibitors/ARBs, as hyperkalemia risk is negligible in this population 3, 4

The American College of Dermatology recommends starting with topical minoxidil 5% foam once daily, evaluating response at 3 months initially, then every 3-6 months using standardized photographs, trichoscopy, and hair pull test 1, 2
If suboptimal response after 6-12 months, oral spironolactone 100 mg daily can be added, with concurrent prescription of combined oral contraceptive or hormonal IUD to regulate menses and prevent pregnancy 3, 4

The American Academy of Dermatology advises against discontinuing minoxidil once started, as all gains will be lost, and against routinely monitoring potassium in young healthy women on spironolactone unless risk factors are present 2, 3, 4
Patients should be counseled that hormonal therapy requires several months to show effect, similar to minoxidil's 3-month minimum response time 3

The British Association of Dermatologists notes that if the patient has alopecia areata rather than female pattern hair loss, neither spironolactone nor finasteride is appropriate, and intralesional corticosteroids are first-line for limited patchy disease, and contact immunotherapy for extensive disease 5, 6, 1